Apellis Pharmaceuticals downgraded by Goldman with a new price target
$APLS
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $36.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/9/2025 | $23.00 | Buy → Neutral | BofA Securities |
| 5/9/2025 | $52.00 | Strong Buy → Outperform | Raymond James |
| 4/29/2025 | $44.00 | Overweight | Cantor Fitzgerald |
| 12/17/2024 | $36.00 | Buy → Neutral | Goldman |
| 11/21/2024 | $31.00 | Equal-Weight | Morgan Stanley |
| 10/25/2024 | $25.00 | Sector Perform | RBC Capital Mkts |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 10/16/2024 | Outperform | William Blair |
8-K - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
10-Q - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
DEFA14A - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
Raymond James downgraded Apellis Pharmaceuticals from Strong Buy to Outperform and set a new price target of $52.00
BofA Securities downgraded Apellis Pharmaceuticals from Buy to Neutral and set a new price target of $23.00
Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)